Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 43 | 2026 | 613 | 9.570 |
Why?
|
| Cognitive Dysfunction | 13 | 2026 | 479 | 2.870 |
Why?
|
| Sleep | 13 | 2025 | 895 | 2.540 |
Why?
|
| Sleep Wake Disorders | 7 | 2025 | 315 | 1.920 |
Why?
|
| Neurodegenerative Diseases | 3 | 2023 | 144 | 1.850 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2024 | 83 | 1.610 |
Why?
|
| REM Sleep Behavior Disorder | 5 | 2026 | 17 | 1.490 |
Why?
|
| Disorders of Excessive Somnolence | 4 | 2021 | 38 | 1.300 |
Why?
|
| Cognition | 6 | 2025 | 1286 | 1.230 |
Why?
|
| Exercise Therapy | 6 | 2024 | 489 | 1.080 |
Why?
|
| Disease Progression | 11 | 2026 | 2892 | 1.000 |
Why?
|
| Electroencephalography | 5 | 2023 | 570 | 0.950 |
Why?
|
| Brain | 5 | 2025 | 3009 | 0.820 |
Why?
|
| Deep Brain Stimulation | 4 | 2025 | 222 | 0.780 |
Why?
|
| Restless Legs Syndrome | 2 | 2021 | 20 | 0.770 |
Why?
|
| Physical Fitness | 1 | 2024 | 209 | 0.740 |
Why?
|
| Subthalamic Nucleus | 4 | 2025 | 85 | 0.720 |
Why?
|
| Aged | 35 | 2026 | 26516 | 0.650 |
Why?
|
| Activities of Daily Living | 4 | 2024 | 449 | 0.600 |
Why?
|
| Polysomnography | 4 | 2026 | 240 | 0.580 |
Why?
|
| Middle Aged | 33 | 2026 | 36821 | 0.540 |
Why?
|
| Pedestrians | 1 | 2017 | 9 | 0.520 |
Why?
|
| Aging | 2 | 2025 | 1992 | 0.500 |
Why?
|
| Humans | 58 | 2026 | 147306 | 0.490 |
Why?
|
| Glutamate Decarboxylase | 1 | 2016 | 166 | 0.450 |
Why?
|
| Safety | 1 | 2017 | 358 | 0.450 |
Why?
|
| Status Epilepticus | 1 | 2016 | 71 | 0.440 |
Why?
|
| Male | 36 | 2026 | 73954 | 0.400 |
Why?
|
| Quality of Life | 7 | 2024 | 3246 | 0.390 |
Why?
|
| Female | 36 | 2026 | 80081 | 0.390 |
Why?
|
| Anticonvulsants | 1 | 2016 | 253 | 0.390 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2026 | 59 | 0.390 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 434 | 0.380 |
Why?
|
| Case-Control Studies | 6 | 2023 | 3660 | 0.380 |
Why?
|
| Kynurenine | 1 | 2013 | 114 | 0.370 |
Why?
|
| Longitudinal Studies | 8 | 2026 | 3029 | 0.370 |
Why?
|
| Neuropsychological Tests | 5 | 2026 | 1145 | 0.370 |
Why?
|
| Huntington Disease | 2 | 2025 | 61 | 0.360 |
Why?
|
| alpha-Synuclein | 3 | 2021 | 47 | 0.350 |
Why?
|
| Seizures | 1 | 2016 | 491 | 0.340 |
Why?
|
| Exercise | 4 | 2020 | 2219 | 0.340 |
Why?
|
| Depression | 2 | 2018 | 1599 | 0.320 |
Why?
|
| Machine Learning | 3 | 2026 | 596 | 0.300 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2021 | 96 | 0.300 |
Why?
|
| Aphasia | 2 | 2021 | 25 | 0.300 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 67 | 0.290 |
Why?
|
| Tremor | 3 | 2023 | 98 | 0.290 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 6011 | 0.290 |
Why?
|
| Dopamine Agents | 2 | 2019 | 22 | 0.270 |
Why?
|
| Goals | 2 | 2020 | 186 | 0.270 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 8432 | 0.240 |
Why?
|
| Oxidative Stress | 1 | 2013 | 1368 | 0.240 |
Why?
|
| Gray Matter | 2 | 2024 | 97 | 0.240 |
Why?
|
| Essential Tremor | 1 | 2026 | 24 | 0.230 |
Why?
|
| Anxiety | 3 | 2024 | 1149 | 0.230 |
Why?
|
| Phototherapy | 1 | 2025 | 50 | 0.220 |
Why?
|
| Neurological Rehabilitation | 1 | 2025 | 16 | 0.220 |
Why?
|
| Music Therapy | 1 | 2025 | 24 | 0.220 |
Why?
|
| Walking | 2 | 2022 | 549 | 0.220 |
Why?
|
| Magnetoencephalography | 1 | 2025 | 161 | 0.210 |
Why?
|
| Motor Skills | 1 | 2025 | 104 | 0.200 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 2017 | 0.200 |
Why?
|
| Wakefulness | 1 | 2025 | 171 | 0.200 |
Why?
|
| Membrane Potentials | 2 | 2022 | 278 | 0.200 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2023 | 4 | 0.190 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 491 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 2974 | 0.180 |
Why?
|
| Wavelet Analysis | 1 | 2022 | 6 | 0.180 |
Why?
|
| White Matter | 1 | 2024 | 170 | 0.180 |
Why?
|
| Walking Speed | 1 | 2022 | 53 | 0.170 |
Why?
|
| tau Proteins | 2 | 2019 | 108 | 0.170 |
Why?
|
| Biomarkers | 5 | 2022 | 4354 | 0.170 |
Why?
|
| Phenylalanine | 1 | 2021 | 69 | 0.160 |
Why?
|
| Carbamates | 1 | 2021 | 51 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2024 | 1912 | 0.160 |
Why?
|
| Circadian Rhythm | 1 | 2025 | 514 | 0.160 |
Why?
|
| Stroke | 2 | 2021 | 1287 | 0.160 |
Why?
|
| Fear | 1 | 2024 | 373 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2024 | 1504 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2026 | 8166 | 0.150 |
Why?
|
| Adult | 11 | 2025 | 41406 | 0.150 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2019 | 44 | 0.140 |
Why?
|
| Self Report | 2 | 2024 | 887 | 0.140 |
Why?
|
| Biological Products | 1 | 2022 | 258 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3980 | 0.140 |
Why?
|
| Language Therapy | 1 | 2018 | 8 | 0.130 |
Why?
|
| Vaccines | 1 | 2022 | 389 | 0.130 |
Why?
|
| Substantia Nigra | 1 | 2017 | 64 | 0.130 |
Why?
|
| High-Intensity Interval Training | 1 | 2017 | 45 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 679 | 0.120 |
Why?
|
| Neurologic Examination | 1 | 2017 | 132 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2021 | 646 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2025 | 11947 | 0.120 |
Why?
|
| Virtual Reality | 1 | 2017 | 82 | 0.120 |
Why?
|
| Saliva | 1 | 2017 | 252 | 0.110 |
Why?
|
| Mental Health | 1 | 2022 | 813 | 0.110 |
Why?
|
| Attention | 1 | 2017 | 464 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 639 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2026 | 104 | 0.100 |
Why?
|
| Peptides | 1 | 2019 | 1003 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2015 | 312 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 2030 | 0.090 |
Why?
|
| Age Factors | 2 | 2017 | 3372 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1162 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 6164 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 5478 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2016 | 1513 | 0.070 |
Why?
|
| Prognosis | 1 | 2017 | 4384 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2023 | 6099 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2025 | 1147 | 0.060 |
Why?
|
| Young Adult | 3 | 2021 | 14437 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 90 | 0.050 |
Why?
|
| Functional Laterality | 2 | 2018 | 241 | 0.050 |
Why?
|
| Actigraphy | 1 | 2025 | 148 | 0.050 |
Why?
|
| Loneliness | 1 | 2024 | 69 | 0.050 |
Why?
|
| Cytokines | 2 | 2022 | 2087 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 3448 | 0.050 |
Why?
|
| Fatigue | 1 | 2025 | 367 | 0.050 |
Why?
|
| Affect | 1 | 2024 | 323 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2026 | 1518 | 0.040 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 99 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2024 | 327 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2023 | 320 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2025 | 724 | 0.040 |
Why?
|
| Levodopa | 1 | 2020 | 40 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 277 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 590 | 0.040 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2019 | 5 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 45 | 0.040 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2019 | 18 | 0.040 |
Why?
|
| Movement | 1 | 2021 | 293 | 0.040 |
Why?
|
| Exercise Test | 1 | 2022 | 636 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 3216 | 0.030 |
Why?
|
| Executive Function | 1 | 2023 | 472 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 40 | 0.030 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 44 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2016 | 17561 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1777 | 0.030 |
Why?
|
| Hippocampus | 1 | 2023 | 989 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2019 | 386 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2026 | 3784 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 2080 | 0.030 |
Why?
|
| Internationality | 1 | 2016 | 156 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 1302 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2017 | 251 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 137 | 0.030 |
Why?
|
| Unemployment | 1 | 2015 | 43 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1721 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1868 | 0.030 |
Why?
|
| Ataxia | 1 | 2015 | 69 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 550 | 0.030 |
Why?
|
| Postural Balance | 1 | 2017 | 254 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 342 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2017 | 698 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 794 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2019 | 935 | 0.020 |
Why?
|
| Electrodes, Implanted | 1 | 2013 | 114 | 0.020 |
Why?
|
| Oxygen | 1 | 2018 | 998 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2021 | 2470 | 0.020 |
Why?
|
| Inflammation | 1 | 2024 | 2921 | 0.020 |
Why?
|
| Risk Factors | 1 | 2026 | 11017 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2019 | 4170 | 0.020 |
Why?
|
| Research | 1 | 2015 | 435 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 537 | 0.020 |
Why?
|
| Neurons | 1 | 2020 | 1672 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1672 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 2142 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 2889 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2434 | 0.010 |
Why?
|
| United States | 1 | 2017 | 16313 | 0.010 |
Why?
|